Drug Search Results
More Filters [+]

Albusomatropin

Alternative Names: albusomatropin, tv-1106, tv1106, tv 1106
Latest Update: 2022-01-21
Latest Update Note: Clinical Trial Update

Product Description

Human serum albumin fused to the N-terminus of growth hormone (Sourced from: https://chem.nlm.nih.gov/chemidplus/rn/1613273-96-3)

Mechanisms of Action: Growth Hormone Analogue

Novel Mechanism: No

Modality: Fusion Protein

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Teva
Company Location: PETACH TIKVA L3 49131
Company CEO: Kåre Schultz
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Albusomatropin

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Hypopituitarism|Pituitary Diseases|Dwarfism, Pituitary|Deficiency Diseases

Phase 2: Hypopituitarism|Dwarfism, Pituitary|Deficiency Diseases|Pituitary Diseases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2014-002736-13

P3

Terminated

Hypopituitarism

2017-08-19

TV1106-IMM-20001

P2

Terminated

Hypopituitarism|Dwarfism, Pituitary

2016-04-30

32%

2013-004468-69

P2

Terminated

Hypopituitarism

2016-04-29

TV1106-IMM-30022

P3

Terminated

Hypopituitarism|Dwarfism, Pituitary|Pituitary Diseases|Deficiency Diseases

2016-02-29

95%

Recent News Events

Date

Type

Title